Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.47 |
| ▸ | HTR6 | P50406 | 5/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | UBE2N | P61088 | 1/20 | 0.37 |
| ▸ | TNFSF11 | O14788 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30831360 | 1.00 | KDM1A (0.47) | KDM1AHTR6MAOAMAOBKCNH2 | |
| SCHEMBL28440363 | 0.94 | KDM1A (0.48) | KDM1AHTR6MAOAMAOBKCNH2 | |
| SCHEMBL27883477 | 0.90 | HTR6 (0.53) | KDM1AHTR6KCNH2TNFSF11 | |
| SCHEMBL28897411 | 0.89 | KDM1A (0.46) | KDM1AHTR6MAOAMAOBKCNH2 | |
| SCHEMBL28450726 | 0.86 | PPARG (0.45) | KDM1AHTR6KCNH2ALOX5PTGS2 | |
| SCHEMBL28436683 | 0.85 | PTGDR2 (0.47) | KDM1AHTR6MAOAMAOBKCNH2 | |
| SCHEMBL26983486 | 0.82 | HTR6 (0.60) | KDM1AHTR6ALKKDM4EUBE2N | |
| SCHEMBL16595062 | 0.81 | HTR6 (0.59) | KDM1AHTR6ALKKDM4EUBE2N | |
| SCHEMBL28438741 | 0.79 | KDM1A (0.46) | KDM1AHTR6KCNH2ALOX5PTGS2 | |
| SCHEMBL28436678 | 0.79 | PTGDR2 (0.48) | KDM1AHTR6MAOAMAOBKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113880815-B | Indole derivatives, preparation method and application thereof | 中国药科大学 | 2024-03-29 | — | — | CN | disclosed |
| CN-113880815-A | Indole derivatives and preparation method and application thereof | 中国药科大学 | 2022-01-04 | — | — | CN | disclosed |
| CN-111533738-A | Compound containing indole structure or pharmaceutically acceptable salt thereof, preparation method and application | 中国药科大学 | 2020-08-14 | — | — | CN | disclosed |
| CN-111518012-A | Compound containing phenylthioether structure or pharmaceutically acceptable salt thereof, preparation method and application | 中国药科大学 | 2020-08-11 | — | — | CN | disclosed |
| US-20190002444-A1 | CRYSTALLINE FORMS OF VILAZODONE HYDROCHLORIDE AND VILAZODONE FREE BASE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2019-01-03 | — | — | US | disclosed |
| US-10011590-B2 | Crystalline forms of vilazodone hydrochloride and vilazodone free base | DR. REDDY'S LABORATORIES LIMITED (IN) | 2018-07-03 | — | — | US | disclosed |
| US-20170217939-A1 | CRYSTALLINE FORMS OF VILAZODONE HYDROCHLORIDE AND VILAZODONE FREE BASE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2017-08-03 | — | — | US | disclosed |
| EP-2900658-A2 | PROCESSES AND POLYMORPHS OF 5-[4-[4-(5-CYANO-1H-INDOL-3-YL) BUTYL]-1-PIPERAZINYL]-2-BENZOFURAN CARBOXAMIDE AND ITS SALTS | MSN Laboratories Limited (IN) | 2015-08-05 | — | — | EP | disclosed |
| US-20150126525-A1 | CRYSTALLINE FORMS OF VILAZODONE HYDROCHLORIDE AND VILAZODONE FREE BASE | REDDYS LAB LTD DR (IN) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126525-A1 | CRYSTALLINE FORMS OF VILAZODONE HYDROCHLORIDE AND VILAZODONE FREE BASE | VIL1, VMA21, PYGL | KDM1A 2286/4885HTR6 1873/4885MAOA 3119/4885 |
| US-20170217939-A1 | CRYSTALLINE FORMS OF VILAZODONE HYDROCHLORIDE AND VILAZODONE FREE BASE | VIL1, VMA21, PYGL | KDM1A 3034/4885HTR6 2054/4885MAOA 2929/4885 |
| US-10011590-B2 | Crystalline forms of vilazodone hydrochloride and vilazodone free base | VIL1, VMA21, PYGL | KDM1A 3034/4885HTR6 2054/4885MAOA 2929/4885 |
| US-20190002444-A1 | CRYSTALLINE FORMS OF VILAZODONE HYDROCHLORIDE AND VILAZODONE FREE BASE | VIL1, VMA21, PYGL | KDM1A 3034/4885HTR6 2054/4885MAOA 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.